Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
GABA(A) receptor (GABAR) |
Target Info
|
Modulator |
[1] |
| References |
Top |
| REF 1 |
FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215904.
|
| REF 2 |
ClinicalTrials.gov (NCT01963208) Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension. U.S. National Institutes of Health.
|
| REF 3 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
